By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


TWi Pharmaceuticals, Inc. 

4F, No. 41, Lane 221
Kang Chien Rd.
Nei Hu Dist.  Taipei  114 
Phone: 886-2-26573350 Fax: 886-2-26573391




Company News
TWi Pharmaceuticals, Inc. Announces That It Will Sell Its Products In The U.S. Market, Originally Planned To Be Sold By Teva, Through Its Wholly-Owned Subsidiary, TWi Pharmaceuticals USA 2/24/2015 6:52:20 AM
Supernus Pharmaceuticals (SUPN) Sues TWi Pharmaceuticals, Inc. For Infringement Of Oxtellar XR® Patents 1/22/2015 8:14:41 AM
TWi Pharmaceuticals, Inc. Receives Approval Of Protocol For Its Drug Ac-201 Controlled-Release Tablet, Phase 2 Clinical Trial In Both The United States And Taiwan 12/12/2014 7:24:31 AM
TWi Pharmaceuticals, Inc. Receives U.S. FDA Approval On Generic Donepezil Hydrochloride Tablets USP, 23 Mg, Its Fifth ANDA From U.S. FDA 10/30/2014 7:41:56 AM
TWi Pharmaceuticals, Inc. Receives FDA Final Approval On Generic Megestrol Acetate 125mg/Ml Oral Suspension 8/28/2014 11:14:55 AM
TWi Pharmaceuticals, Inc. Announces Settlement Of Lidoderm® Patent Litigation 4/23/2014 8:58:31 AM
TWi Pharmaceuticals, Inc.i Announces ANDA Approval Of Generic Procardia Xl® Tablets 30 Mg, 60 Mg And 90 Mg In The United States 4/7/2014 9:28:15 AM
TWi Pharmaceuticals, Inc. Receives Patent Allowance for Its Reduced Food Effect Metformin Controlled Release Formulation in United States 7/16/2013 10:39:53 AM
TWi Pharmaceuticals, Inc.' Manufacturing Site for the Generic Version of Lidoderm(R) (Lidocane 5% patch) Passes US FDA cGMP Audit and Pre-Approval Inspection 5/29/2013 10:05:00 AM
TWi Pharmaceuticals, Inc. Announces Tentative ANDA Approval for Guanfacine Hydrochloride Extended-Release Tablets 5/14/2013 9:35:08 AM